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Abstract
Background: Breathlessness is common and distressing in advanced disease. This phase II study aimed to
determine the use and acceptance of a hand-held fan (HHF) to relieve breathlessness, to test the effectiveness of
the HHF and to evaluate the recruitment into the study.
Methods: RCT embedded within a longitudinal study testing a HHF over time compared to a wristband. Patients
were included in the longitudinal study when suffering from breathlessness due to advanced cancer or COPD III/IV
and could opt in the RCT. Primary outcome was use of the HHF and the wristband after two months. Secondary
outcomes were recruitment into the trial and change of breathlessness severity after two months, measured on
the modified Borg scale. Baseline data were collected in a personal interview and follow-up data by monthly postal
questionnaires.
Results: 109 patients were recruited in the longitudinal study of which 70 patients (64%) participated in the RCT.
Non-participants had statistically significant less breathlessness (Borg mean 2.6 (SD 1.48) versus 3.7 (SD 1.83); p =
0.003) and a better functional status (Karnofsky status mean 61.9 (SD 11.2) versus 66.7 (SD 11.0); p = 0.03). Attrition
due to drop out or death was high in both groups. After two months, about half of the patients used the HHF but
only 20% the wristband without a statistical difference (Fisher’s exact test p = 0.2). 9/16 patients judged the HHF as
helpful after two months and 4/5 patients the wristband. There was no difference in mean breathlessness change
scores between the HHF (Borg change score: mean 0.6 (SD 2.10)) and the wristband (mean 0.8 (SD 2.67)) after two
months (p = 0.90).
Conclusions: Symptom burden and low functional status did not restrain patients from participation in the study.
Finding a control for a visible intervention is challenging and needs careful consideration to what is acceptable to
patients. The preliminary evidence of effectiveness of the HHF could not be proved. Patients often stopped using
the HHF but a small group seemed to benefit which was not necessarily related to a relief in breathlessness.
Therefore, more work is necessary on selecting and identifying those who might benefit from the HHF.
Trial registration: ClinicalTrials.gov Identifier: NCT01123902.
Background
Breathlessness is a common and distressing symptom in
advanced disease [1] which is still poorly understood
and not managed satisfactorily [2]. Many non-pharma-
cological interventions are available which may comple-
ment pharmacological interventions in the management
of breathlessness [3]. However, the evidence is scarce
for some of these interventions, e.g. a hand-held fan
(HHF). This simple and cheap device is easy to use and
it is one of the few interventions that can be used by
the patients independent of any clinician or setting.
A HHF produces a flow of air which may alter ventila-
tion when directed to the face, nasal mucosa, or pharynx
[4] but the exact mechanism of this effect is unclear. It
has been used successfully to reduce breathlessness in
healthy participants where breathlessness was induced
through inspiratory resistive load [4]. Two studies tested
the HHF in patients [5,6]. A small pilot study in six
COPD patients did not show sufficient improvement of
breathlessness [5] but an adequately powered crossover
trial in 50 palliative care patients showed a significant
improvement in breathlessness [6]. This latter study
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and crossed over to the other treatment with a 10 min-
utes washout period. As the results of this study were
promising, the HHF should be tested in a real world set-
ting where patients use it over time. However, before
setting up an adequately powered RCT we felt that a
number of questions needed to be addressed about the
feasibility of such a study. Therefore, we ran an explora-
tory phase II study to test a HHF for breathlessness
which aimed to evaluate the use and acceptance of the
intervention and the control, the potential effectiveness
of the HHF, the recruitment into the study, and collect-
ing data for calculating a sample size.
Methods
Design
As we wanted to assess how the HHF worked over time,
we embedded this RCT in a longitudinal cohort study
which aimed to describe the course of breathlessness
over time [7].
Setting and recruitment
Recruitment to the longitudinal study took place from
the oncology and/or respiratory departments in three
major hospitals (one tertiary respiratory hospital), a
hospice home care service and two respiratory prac-
tices in Munich, Germany. All recruitment sites
screened patients regularly for inclusion criteria, and
patients in the respiratory hospital were screened at
regular weekly visits. The longitudinal and RCT com-
ponents were explained in more detail to patients
interested in the study, and an information leaflet was
provided. There was one consent form for both studies
but patients were given the option to participate only
in the longitudinal study and not in the RCT. Reasons
for refusal to participate in the RCT were recorded.
Data were collected from June 2006 to November
2007.
Patients
Patients were included if they reported breathlessness
which had an impact on their daily life and were suffer-
ing from one of the following conditions:
￿ Advanced malignant disease (primary lung cancer
or secondary lung metastases/lung involvement due
to cancer).
￿ COPD stage III (severe) and IV (very severe)
according to GOLD criteria [8].
Patients were excluded if unable to provide informed
consent, too ill to be interviewed and not fluent or lit-
erate in German. There were no additional exclusion
criteria for the RCT.
Randomisation and allocation concealment
A computer-generated random number list was pro-
duced using stratified randomisation with blocks of six
to ensure exactly equal treatment numbers at certain
equally spaced points in the sequence of patient assign-
ments [9]. COPD and cancer were determined as strata
and a separate randomisation list was prepared for each
stratum. After consent and baseline interview, randomi-
sation was conducted using an independent individual
who opened prepared and sealed envelopes.
Intervention and control
The intervention to be tested was a HHF directed to the
area of the face innervated by the second and third tri-
geminal nerve branches. At the first contact, patients
received a HHF and the researcher demonstrated how
to use the HHF showing the appropriate area around
the central part of the face, the sides of the nose and
above the upper lip. The HHF had three soft rotor
blades and an unfoldable rotor unit. Patients also
received an information leaflet with a picture of a HHF,
explanations and instructions for the use of the HHF.
A wristband was chosen as control under the assump-
tion that distraction could serve as a placebo and was
more realistic than directing the fan towards the leg as
in a previous study [6]. At the first contact, patients
received a plastic wristband labelled “breathe easy”.
They were instructed to wear the wristband continually
and pull it regularly at short intervals when breathless
or during breathlessness attacks. Patients in this group
received a similar information leaflet as the HHF group
but for the use of the wristband.
Both patient groups received standard care supplied
by local services including general practitioners, district
nurses, specialist respiratory medicine or oncology, and
potentially palliative care.
Outcomes
The primary outcome for this study was the use of the
HHF and the wristband after two months. Secondary
outcomes were helpfulness of the HHF and the wrist-
band after two months, change of breathlessness severity
between baseline and month two, and uptake into the
trial (proportion of patients from the longitudinal study
participating in the RCT). We were also interested in
patients’ experiences using the HHF and the wristband.
To assess patients’ use, helpfulness and experiences
with the HHF and the wristband over time, specific ques-
tions were asked monthly over six months as part of the
questionnaires in the longitudinal study (see Table 1).
The modified Borg scale, a categorical scale with ratio
properties, was used to assess the average severity
of breathlessness over the last 24 hours [10-12].
Borg scores range from 0 (no breathlessness) to 10
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respiratory medicine and has been used with cancer
patients [13].
Timing of data collection
Data collection used an initial face to face interview;
patients were followed by monthly postal questionnaires
for six months or until the patient died.
Analysis
Demographic and clinical characteristics of patients tak-
ing part in the RCT and those refusing to participate
were compared, using unpaired t-tests for continuous
and c2-tests for categorical variables.
We compared the proportion of patients being alive who
reported using the HHF or the wristband after two months,
and also the helpfulness of both, using Fisher’s exact test
for small frequencies. Patients’ comments on their experi-
ences with the HHF and the wristband were collated and
grouped in different categories (positive effects, negative
effects or disbeliefs, not used and no answer).
To compare the effect of the HHF and the wristband
on breathlessness, regression analysis was performed on
breathlessness change scores after two months and
adjusted for baseline differences. Analysis was on the
basis of intention to treat where people were assigned to
original groups irrespective of the use of the HHF or
wristband. The significance level was set at p < 0.05.
The data was analysed using the software package
STATA IC10.
We calculated the effect size d of the HHF with the
following formula
d
MM
SD SD
=
−
+
12
12 2
22 () /
with M1 as the mean of the intervention group and
M2 the mean of the control group [14]. Cohen (1988)
defined effect sizes as “small, d =. 2 , ”“ medium, d =. 5 , ”
and “large, d =. 8 ” [14]. With the information from this
s t u d yw ee s t i m a t e das a m p l es i z ef o rab i g g e rt r i a la tp
< 0.05 and a power of 80%.
Sample size calculation
As this was a phase II trial we did not estimate a prior
sample size. Instead we aimed to estimate an effect size
for a phase III trial. The sample size for the longitudinal
study has been set at 85 to show a difference of 1.0 on
the Borg scale between the two groups with a standard
deviation of 2.1.
We estimated that about 30 patients in each arm
would give sufficient information on the feasibility of
the intervention, and allow calculation of an effect size.
Ethics approval was obtained from the College Research
Ethics Committee at King’s College London (CREC num-
ber 05/06-69) and from the Research Ethics Committee
of the University of Munich (number 079-06).
Results
109 patients were recruited in the longitudinal study.
39/109 enrolled patients declined to participate in the
RCT. Main reasons for refusal were lack of belief in the
intervention or control (n = 15), not suffering from dys-
pnoea attacks (n = 6) and feeling irritated by cold air
draught (n = 5). Of the remaining seventy patients, 38
were randomised to the HHF (24 COPD and 14 cancer
patients) and 32 to the use of the wristband (21 COPD
and 11 cancer patients) (see Figure 1 CONSORT dia-
gram). Main reasons for loss of follow-up were non-
return of questionnaires.
Demographic and clinical characteristics
Participants and non-participants in the RCT were simi-
lar regarding age and gender but more cancer than
COPD patients refused to take part in the RCT (see
Table 2). Non-participants had less severe breathlessness
(t = -3.09, p = 0.003) and a better functional status (Kar-
nofsky performance status, KPS) compared to those par-
ticipating (t = 2.16, p = 0.03).
Of those patients entering the RCT, the demographic
and clinical variables were similar in the HHF and the
wristband group regarding age, gender, diagnoses,
breathlessness and use of oxygen (see Table 3).
Attrition
The proportion of attrition and missing data was con-
siderable in both groups. After two months, 13% of 38
patients (5 patients, 4 cancer) have died in the interven-
tion and 22% of 32 patients in the control group (7
patients, 6 cancer). Overall, 29% of 38 patients (11
patients; 9 cancer) died in the intervention and 41% of
32 patients (13 patients, 10 cancer) in the control group
during the six months of the study. Additional missing
data were mainly related to intermittent missing ques-
tionnaires due to deterioration and questionnaire fati-
gue. Overall, missing data was higher in the control
group (up to 60%) than in the intervention group (up to
Table 1 Questions on use and experiences with hand-
held fan or wristband
Question Answer options
1. How often do you use the hand-held fan/
wristband?
daily, occasionally,
not at all
2. Do you find the hand-held fan/wristband
helpful?
yes, no, don’t know
3. What are your experiences with the hand-held
fan/wristband?
Free text
4. Do you have any comments regarding the
hand-held fan/wristband?
Free text
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our main intention was the feasibility of such a study
and also exploring the nature of missing data.
Did participants use the hand-held fan and the wristband
and was it helpful?
After two months, 16/33 (48%) patients being alive used
the HHF, nine daily and seven occasionally. In the wrist-
band group, 5/25 (20%) patients being alive used it, one
patient daily and four patients occasionally (see Figure
2). There was no statistical difference between the two
groups (Fisher’s exact p = 0.2).
T h eo v e r a l lu s eo v e rt i m ev a r i e di nb o t hg r o u p s .T h e
number of patients using the HHF regularly dropped
after two months considerably whereas the proportion
of patients using the wristband was low from the first
month on (see Figure 2).
At month two, 23 patients reported on the helpfulness
of the HHF with nine considering it as helpful and 14
not. Of the 11 patients commenting on the helpfulness
of the wristband four considered it to be helpful and
seven not. Those not using the HHF or the wristband
judged it as unhelpful. The difference in outcome was
not statistically significant (Fishers exact test, p = 0.5).
Effect of hand-held fan and wristband on breathlessness
After two months, data for change scores was available
from 24 patients in the intervention and 12 patients in the
Figure 1 CONSORT diagram showing the flow of patients through the study.
Table 2 Demographics of 70 patients taking part in the RCT and 39 patients excluded from the RCT
RCT group (n = 70) Not included in RCT (n = 39) Comparison between groups
Age 65.6 (8.80) 62.7 (10.21) t = -1.56, p = 0.12
gender (m/f) m 36/f 34 m 18/f 21 c2 = 0.28, p = 0.6
COPD (n = 60)
Cancer (n = 49)
45
25
15
24
c2 = 6.75, p = 0.009
Borg scale 3.7 (1.83) 2.6 (1.48) t = -3.09, p = 0.003
KPS 61.9 (11.2) 66.7 (11.0) t = 2.16, p = 0.03
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group was 0.6 (SD 2.10) and 0.8 (SD 2.67) for the control
group without a statistically significant difference after
adjusting for baseline Borg scores (t = 0.13, p = 0.90).
What experiences did participants have using the hand-
held fan or the wristband?
All comments of each patient were summarized to
achieve an overall judgement of the experiences. 13/38
patients randomised to the use of the HHF judged their
experiences as positive at some point during the study.
They commented the HHF as “very good, use it regu-
larly” (COPD patient), “very helpful, don’tw a n tt om i s s
it anymore, makes life much easier” (COPD patient) or
“helps breathing easier if you put it directly in front of
mouth and nose” (COPD patient). Seven patients
expressed negative experiences regarding the HHF
reporting “it makes me nervous” (COPD patient) or “it
is more like a toy, but doesn’th e l p ” (COPD patient).
Two patients reported that the HHF was defective. One
patient was very sensitive to the air draught produced
by the HHF. Eight patients did not comment further on
their experiences. Patients testing the wristband
reported the following: 5/32 patients expressed positive
experiences such as “it is reassuring to wear it” (COPD
patient) or “Ir e l yo ni t ” (cancer patient). Four patients
w e r er a t h e rn e g a t i v ep o i n t i n go u tt h a ti ti s“foolish”
(cancer patient) or “not helpful” (COPD patient). Two
patients reported skin irritations and two patients did
not use it of whom one complained that the wristband
did not fit. Two patients had mixed experiences and
seven patients did not comment further on their
experiences.
Calculation of effect size and sample size
Taking data from the second month with 12 patients in
each group, we should have been able to detect an effect
s i z eo f2 . 5( p o w e ro f8 0 % ,5 %s i g n i f i c a n c el e v e l ) .H o w -
ever, calculating the actual effect size with the results of
the second months gave us a value of -0.08.
Discussion
The results of this phase II study give helpful insights
regarding recruitment, use and acceptance of a non-
pharmacological intervention, and selection of a control,
for conducting a longitudinal RCT to test a non-phar-
macological intervention in a palliative care population.
Recruitment into the study
First, a two step approach was chosen to recruit patients
into the RCT. All participants in the longitudinal study
were invited to enter the RCT. However, only two thirds
of patients took part in the RCT and a considerable
number of patients opted out of the trial. Reasons for
non-participation varied from irritation by cold air to
lack of belief in the intervention or the control. It can
only be surmised why patients believed neither in the
intervention nor the control. A HHF is a simple device
Table 3 Demographics of 70 patients taking part in the RCT
Fan (n = 38) Wristband (n = 32) Comparison between HHF and wristband
Age 64.5 (9.88) 66.6 (7.79) t = 0.997, p = 0.32
gender (m/f) m 19/f 19 m 17/f 15 c2 = 0.07, p = 0.79
COPD
Cancer
24
14
21
11
c2 = 0.33, p = 0.57
Borg scale 4.0 (1.86) 3.3 (1.77) t = 1.42, p = 0.16*
KPS 62.4 (10.5) 61.2 (12.1) t = 0.41, p = 0.68
*Mann Whitney U not significant.
Figure 2 Use of HHF (n = 38) and wristband (n = 32) over time.
(note: numbers in bars are absolute numbers).
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get rather than a tool that could relieve their breathless-
ness. Or some might expect a more technical device
especially when already on long-term oxygen.
A strength of this study is the provision of baseline
data of non-participants to allow comparisons with
those participating in the trial. It is noteworthy that
patients who refused participation in the RCT had less
breathlessness and a better functional status compared
to those who participated. Hence, RCT-participants
were more ill than their counterparts. It can be assumed
that those participating were more motivated to try
something to relieve their breathlessness. Patients’ physi-
cal status and symptom burden are a regular argument
for gate keeping in palliative care research [15]. Data
from this study further disproves the widely held opi-
nion that patients towards the end of life may be too ill
to take part in trials in palliative care.
Acceptance of intervention and feasibility of control
Collecting data on use and experiences of patients with
the intervention and the control allowed us to assess the
acceptance and feasibility of both. Overall use of the
HHF and the wristband was not as high as expected. In
the second month, about 40% of the patients rando-
mised to the HHF actually used it and of those about
half found it helpful. The benefit from the HHF was not
necessarily related to a relief in breathlessness severity.
Thus, further research should identify those patients
who benefit from the HHF and explore reasons for the
beneficial effect. However, for most patients neither the
HHF nor the wristband was popular. This is reflected in
the considerable number of patients discontinuing either
the intervention or the control or dropping out from
the study.
For many patients who were invited to the RCT or
even for those who took part, the wristband did not
seem an acceptable control. This is also reflected in the
comments of some patients after randomisation to the
wristband that they would have preferred the HHF as
they did not believe in the wristband. Compliance with
the control was low from the beginning. Patients’ prefer-
ences not only influence participation in randomised
trials [16] but are also associated with treatment effects
[17]. There is some evidence that preferences can mod-
ify treatment outcomes (especially in the preferred treat-
ment group) but it has also been shown that
participants allocated to their undesired treatment were
less likely to be lost to follow-up [17]. This finding is in
contrast to the observations in this study.
Finding a suitable control for a non-pharmacological
intervention such as the HHF is a challenge. It has been
s u g g e s t e dt h a tt h ec h o i c eo fac o n t r o ls h o u l db es u p -
ported by a systematic review [18]. A Cochrane Review
on non-pharmacological interventions to relieve breath-
lessness was conducted in advance [3]. The two previous
studies testing the HHF either added the fan to nasal
cannulae with the flow of oxygen or directed the fan to
the patient’s leg [5,6]. Both options may be useful in a
more controlled setting but would not be applicable in a
long term outpatient setting as in this trial. The combina-
tion with oxygen would have been a co-intervention and
not all patients were on oxygen. Also, repeated direction
of the HHF towards the leg did neither seem practical
nor plausible for patients. Several other options have
been considered for the control. One was, to change the
direction of the rotation of the blades of the HHF to
reduce the air flow but this would have been technically
difficult. Another one was to show the patients sham-
acupressure points but it was felt that patients should be
given a device and not only shown a procedure. As cogni-
tive-behavioural strategies play an important role in
modulating the perception of breathlessness [19], distrac-
tion in the form of pulling a wristband when breathless
seemed to be an appropriate alternative.
Effectiveness of hand-held fan
In contrast to previous studies on the use of HHF to
relieve breathlessness [5,6], this study did not show a
benefit of the HHF. Baltzan demonstrated transient relief
of breathlessness from a fan blowing onto the face in a
small group of COPD patients during an exercise test [5].
In a different study, Galbraith tested the effect of the
HHF in a cross-over RCT in patients with advanced dis-
ease [6]. This study showed a benefit of the HHF in
relieving breathlessness. Both studies used the fan only
over a short time period, Baltzan over three days and
Galbraith only once. As both studies lacked follow-up,
the long-term effects of the HHF were unclear. Partici-
pants in our trial did not use the HHF or the wristband
consistently over time and potential reasons for this have
been discussed above. It could also be surmised whether
there are cultural differences in Germany regarding the
acceptance of such an intervention and control.
Collecting data for calculating effect size and sample size
A further aim of this study was to collect data for calcu-
lating an effect size to be able to calculate a sample size
for a larger trial. The effect size that we derived from
our data was minimal (-0.08). This low effect size and
the low continued use of the HHF question the value of
the HHF at least in COPD and cancer patients. This
pragmatic phase II trial needs replication as it is in con-
trast to earlier work.
Limitations
Ideally, the intervention in an RCT should be blinded as
otherwise the results may be distorted if patients and/or
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ever, non-blinding would have meant that patients would
have been more likely to report a benefit - and researchers
too. As we didn’t find a benefit it is more likely/impossible
that the result would be found because of non-blinding.
Indeed it makes our negative result more likely.
Blinding of a non-pharmacological intervention such
as the HHF is almost impossible in many cases. If blind-
ing is not feasible one compromise could be to blind
the evaluation and/or the analysis. The first was also not
feasible in this study as patients filled in the postal ques-
tionnaires themselves without a researcher. The second
would have been a potential approach which was not
used in this study but should be considered for future
trials in non-pharmacological interventions.
A further limitation is the small number of patients
providing data for analysis and consequently the loss
of power. Our main aim was to collect information
about the feasibility of testing a HHF and to a lesser
extent to evaluate the effectiveness of the intervention.
Nevertheless, as discussed before, attrition and low
compliance of adherence to the intervention and the
control were considerable and not expected. It was
tried to increase compliance by providing an informa-
tion leaflet and instructions on how to use the device
but reminders and further instructions during the trial
w e r ef o r g o n ea st h eu s eo ft h ed e v i c e so v e rt i m ew a s
one of the outcomes.
Conclusions
This study does not allow a conclusion about the effec-
tiveness of a HHF to relieve breathlessness. However, it
seems that a small group of patients is getting benefit
from a HHF although this may not be related to reduc-
tion of breathlessness severity. As the HHF is a cheap
a n ds i m p l ed e v i c eat r i a lw i th an individual patient
should be considered. Further research should focus not
only on the effectiveness of a HHF but also on predic-
tors for whom it may be helpful.
Findings from this study also support the benefit of
running phase II trials before setting up larger RCTs to
test recruitment and, especially when non-pharmacolo-
gical interventions are tested, the feasibility of the inter-
vention and the control. Selecting a control for a non-
pharmacological intervention is challenging and needs
careful consideration to what is acceptable to patients.
Symptom burden and low functional status did not
restrain patients from participation in the study which
emphasises the importance of giving patients the choice
whether they want to take part in research or not. Tim-
ing of outcome measurement should be closely related
to the intervention under evaluation, especially in a
longitudinal study.
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